Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.
Solid Tumors
DRUG: Iniparib (SAR240550/BSI-201)|DRUG: Carboplatin|DRUG: Doxorubicin HCL liposome injection|DRUG: Gemcitabine|DRUG: Irinotecan|DRUG: Paclitaxel|DRUG: Topotecan
Number of participants with incidence of adverse events by NCI-CTCAE version 4.03, Up to 30 days after last treatment dose
The Treatment Extension protocol consists of three time points/periods: the Screening Period (during which assessments are performed to determine whether the patient meets the criteria to participate in the study), the Treatment Period (during which the patient receives treatment with the study drug(s)), and the Post-Treatment Period (during which patients complete an evaluation approximately 30 days after the last dose of study drug). Patients may continue to participate on the Treatment Extension study as long as they meet criteria to continue to receive therapy, tolerate the treatment regimen, do not develop progressive disease (PD), do not discontinue from iniparib, do not withdraw consent, or until iniparib becomes commercially available.